News
Total margin control surgery warranted for high-risk keratinocyte carcinomas
MILAN – For high-risk cases, CCPDMA has superior outcomes, compared with standard excision, according to results of the meta-analysis.
News
Severity, itch improvements remain steady with ruxolitinib for atopic dermatitis
MILAN – Recruitment of patients in phase 3 studies of ruxolitinib cream for AD has just started.
News
JAK inhibitors are the ‘near future’ of alopecia areata treatment
MILAN – While not yet approved, science, data, and treatment algorithms are lining up in a positive direction.
News
Systemic psoriasis treatments less often prescribed in elderly with psoriasis, despite comparable response rates
MILAN – There was an “imbalance” in the types of medications prescribed for older and younger patients in the registry, with biologics used more...
News
Atopic dermatitis patients achieved freedom from itch on JAK inhibitor upadacitinib
MILAN – Improvements in pruritus occurred early with upadacitinib and were pronounced at the highest dose studied, 30 mg daily.
News
Bullous disorders linked to frequent interruption of immune checkpoint inhibitor treatment
MILAN – It’s not clear why patients receiving cancer immunotherapy treatment develop bullous pemphigoid.
News
Novel immune checkpoint holds ‘great promise’ as melanoma treatment target
MILAN – A monoclonal antibody directed against DC-HIL reduced melanoma growth and metastasis in animal models.
News
Antimalarial may be effective, safe for erosive oral lichen planus
MILAN – In a small retrospective study, 85% of patients treated with the oral antimalarial agent had marked improvement or full remission.
News
Bispecific CAR T-cell therapy yields complete responses in relapsed/refractory non-Hodgkin lymphomas
Development plans for anti-CD19, anti-CD20 therapy include phase 2 studies in mantle cell, CD19 CAR T cell relapsers.
News
Skin plus GI adverse events with checkpoint inhibitors linked to risk of additional adverse events
MILAN – Toxicities occurred early in treatment, and having both increased risk of adverse events in other organ systems.
News
Advanced basal cell carcinoma responds to pembrolizumab in proof-of-concept study
MILAN – Combining pembrolizumab with vismodegib was not clearly superior to pembrolizumab alone in a proof-of-concept study.
News
Antibody targeting ‘do not eat me’ signals is active in AML, MDS
CHICAGO – 5F9 plus azacitidine eradicated leukemia stem cells in responding patients, providing a mechanism for potential long-term durability.
News
Chemo-free Smart Start regimen looks promising in poor-prognosis DLBCL
CHICAGO – There was “oohing and aahing” over results showing high response and survival rates for combined rituximab, lenalidomide, and ibrutinib...
News
Fixed-duration venetoclax-obinutuzumab superior to standard CLL therapy
CHICAGO – The immediately practice changing study offers a time-limited frontline option, one expert reported.
News
Repotrectinib highly active in ROS1-positive lung cancer
Pivotal phase 2 portion of study to commence later this year.